CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 61 enrolled
Drug / intervention
Autologous Platelet Rich Plasma +1 moredrug
Likely dose
Autologous Platelet Rich Plasma 5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04396795
NCT04396795Phase 2Completed

A Randomized Control, Double-Blind, Placebo Controlled, Multicenter Clinical Trial on Safety and Efficacy of Autologous Platelet-Rich Plasma Injection Treatment for Erectile Dysfunction.

University of Miami·interventional·Posted May 21, 2020·Updated Jan 9, 2024

In Brief

A Phase 2 clinical trial evaluating Autologous Platelet Rich Plasma and Saline solution for Erectile Dysfunction. Completed, enrolled 61 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate changes in vascular parameters and International Index of Erectile Function (IIEF) scores with the administration of Platelet Rich Plasma (PRP) to participants with Erectile Dysfunction (ED)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedMay 21, 2020
Enrollment StartMay 21, 2020
Primary CompletionJan 23, 2023
Study CompletionApr 18, 2023
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 6.1 years ago

Interventions

Autologous Platelet Rich Plasmadrug

Each injection session will consist of a total of 5 mL PRP infused slowly over a 2-minute period; 2.5 mL each injected to the right and left corpus cavernosum.

Saline solutionother

Each injection session will consist of a total of 5 mL saline solution infused slowly over a 2-minute period; 2.5 mL each injected to the right and left corpus cavernosum